Risperdal Side-Effect Lawsuits Move Forward With Status Confernce Regarding Anit-Psychotic Drug Side-Effects

Print

Risperdal Side-Effect Lawsuits Alleging Use Of The Antipsychotic Drug Causes Gynecomastia Or Enlarged Male Breasts Are Consolidated In A Mass Tort Program In The Court of Common Pleas In Philadelphia, Pennsylvania.

risperdal-gynecomastia-lawsuits-Wright-and-Schulte-LLCAs the attorneys at Wright & Schulte LLC continue to represent clients in product liability lawsuits the firm notes that litigation continues to move forward for Risperdal side-effect lawsuits. Where a status conference was held this week in the Philadelphia Court of Common Pleas to discuss pending anti-psychotic drug side-effect claims. The 1,300 Risperdal lawsuits are centralized for pretrial proceedings in the Philadelphia court’s mass tort program. The Risperdal complaints are filed on behalf of boys and young men who allege that they developed excessive breast tissue growth, also known as gynecomastia, due to taking the Risperdal antipsychotic drug. The lawsuits contend that Risperdal’s manufacturer and marketer, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., failed to adequately warn doctors and their patients about the risk of developing abnormal breast tissue growth due to using Risperdal. The gynecomastia complaints further contend that Janssen improperly marketed the antipsychotic drug to young males without first receiving approval from the U.S. Food and Drug Administration (FDA) to do so. (In Re: Risperdal Litigation, Case Number 100300296)

“We continue to monitor the Risperdal litigation in the Philadelphia Court of Common Pleas due to the bellwether trial program that is underway for Risperdal cases,” says Wright & Schulte LLC, a law firm with attorneys who aggressively fight for plaintiffs who have been damaged by harmful side-effects of prescription drugs such as Risperdal. “The bellwether trials help parties in the Risperdal litigation, including the court, predict the outcome of similar cases scheduled for trial in the future.”

According to court documents and the FDA, Risperdal is an atypical antipsychotic drug approved by the FDA to treat schizophrenia and bipolar disorder, and irritability in autistic children and adolescents. Risperdal complaints allege that among the most prevelant adverse reactions reported to the FDA regarding the medication is gynecomastia, which is enlargement of male breasts due to the elevation of the female hormone, prolactin. In addition to gynecomastia, Risperdal also carries the side-effect risks of diabetes, hyperglycemia, abnormal pain and involuntary movements of their face and body, according to the FDA. Some of the gynecomastia complaints contend that plaintiffs were young when they were prescribed Risperdal and the FDA had not approve Risperdal for any purpose in children until late 2006. (In Re: Risperdal Litigation, Case Number 100300296)
[accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, June 2009]

The Risperdal attorneys at Wright & Schulte LLC point out that the FDA warned Janssen Pharmaceuticals Inc. about its “misleading marketing messages” to physicians regarding Risperdal and the company’s other antipsychotic drugs. After the FDA’s warning, the U.S. Department of Justice (DOJ) launched a criminal investigation into Janssen’s marketing practices and leveled charges against the company of misbranding and filing false claims for Risperal. According to the DOJ, Johnson & Johnson and Janssen agreed to pay $1.39 million to resolve the claims of off-label marketing and paying kickbacks to physicians who promoted Risperdal and Invega. Additionally, the The DOJ also said that the companies agreed to pay a total of $2.2 billion to resolve all criminal and civil claims brought against them by the justice department.
[justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations, November 4, 2013]

Court documents further indicate that the Philadelphia Court’s bellwether trial program for Risperdal side-effect lawsuits is moving forward with its third trial scheduled on May 11. According to court records, the first of three bellwether trials in the program ended in February with the Philadelphia court jury awarding $2.5 million to a 20-year-old Alabama man who took Risperdal for autism when he was 8 years old and later experienced gynecomastia and weight gain. (Case No. A-196444) The second bellwether trial ended March 20 with the Pennsylvania state court jury deciding in favor of the plaintiff that Johnson & Johnson and its Janssen Pharmaceuticals unit failed to adequately warn about Risperdal’s gynecomastia risk. However, court records show the jury did not award compensation to the plaintiff after determining the plaintiff did not prove that he developed gynecomastia as a result of using Risperdal. (Case No.130301803)

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
1-800-399-0795
www.yourlegalhelp.com

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.